U.S. pharma big copyright scrapped two experimental weight loss tablets very last yr—a the moment-each day tablet, lotiglipron, because of elevated liver enzymes and a 2 times-day-to-day pill, danuglipron, as a consequence of robust Unwanted effects—but CEO Albert Bourla has reported